DGAT-2

Technology

Last mentioned: Feb 24, 2026

Timeline

Dec 31, 2025
Patent Extension

Secured Rezdiffra patent protection through 2045.
Nov 20, 2025
DGAT-2 and siRNA Expansion

Acquired late-stage DGAT-2 inhibitor and six preclinical siRNA assets.
Sep 15, 2025
GLP-1 Acquisition

Madrigal paid $120 million upfront to acquire an oral GLP-1 program.
Mar 1, 2025
Rezdiffra Commercial Launch

First full year of Rezdiffra availability in the U.S. market for MASH.

Stories mentioning DGAT-2 1

pharma Bullish

Madrigal’s Rezdiffra Surpasses $950M in 2025 as Pipeline Expands into GLP-1s

Madrigal Pharmaceuticals reported a transformative 2025, with Rezdiffra net sales reaching $958.4 million during its first full year on the market. The company is aggressively pivoting toward a multi-asset metabolic powerhouse, integrating oral GLP-1 and DGAT-2 programs alongside its core MASH franchise.

Feb 24, 2026 5 sources